Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Professor Declan Mc Loughlin


MEDICAL SCHOOL (Trinity Inst. of Neurosciences (TCIN))

Prof McLoughlin took up the new post of Research Professor of Psychiatry on July 1, 2007. Prior to this I was a Senior Lecturer in the MRC Centre for Neurodegeneration Research at the Institute of Psychiatry, King's College London.
Kolshus E, Jelovac A, McLoughlin DM, Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials - CORRIGENDUM., Psychological medicine, 2018, Journal Article, PUBLISHED
Finnegan M, Bayazit H, Cronin T, Guler K, Galligan T, Karababa FI, McLoughlin DM, Towards International Standards: East Meets West., The journal of ECT, 2018, Journal Article, PUBLISHED
Brennan S, McLoughlin DM, O'Connell R, Bogue J, O'Connor S, McHugh C, Glennon M, Anodal transcranial direct current stimulation of the left dorsolateral prefrontal cortex enhances emotion recognition in depressed patients and controls., Journal of clinical and experimental neuropsychology, 39, (4), 2017, p384-395 , Journal Article, PUBLISHED  DOI
Ryan KM, Glaviano A, O'Donovan SM, Kolshus E, Dunne R, Kavanagh A, Jelovac A, Noone M, Tucker GM, Dunn MJ, McLoughlin DM, Electroconvulsive therapy modulates plasma pigment epithelium-derived factor in depression: a proteomics study., Translational psychiatry, 2017, Journal Article, PUBLISHED
Kolshus E, Jelovac A, McLoughlin DM, Letter to the Editor: Electrode placement in electroconvulsive therapy - bilateral is still the 'gold standard' for some patients: a reply., Psychological medicine, 2017, Journal Article, PUBLISHED
Kolshus E, Jelovac A, McLoughlin DM, Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials., Psychological medicine, 2017, Journal Article, PUBLISHED
Ito M, Bolati K, Kinjo T, Ichimura K, Furuta A, McLoughlin DM, Suzuki T, Arai H, Electroconvulsive stimulation transiently enhances the permeability of the rat blood-brain barrier and induces astrocytic changes., Brain research bulletin, 2017, Journal Article, PUBLISHED
Semkovska M, Landau S, Dunne R, Kolshus E, Kavanagh A, Jelovac A, Noone M, Carton M, Lambe S, McHugh C, McLoughlin DM., Bitemporal Versus High-Dose Unilateral Twice-Weekly Electroconvulsive Therapy for Depression (EFFECT-Dep): A Pragmatic, Randomized, Non-Inferiority Trial., The American journal of psychiatry, 173, (4), 2016, p408-417 , Journal Article, PUBLISHED  DOI
Agyapong VI, Osei A, Mcloughlin DM, McAuliffe E., Task shifting-perception of stake holders about adequacy of training and supervision for community mental health workers in Ghana., Health policy and planning, 31, (5), 2016, p645-655 , Journal Article, PUBLISHED  DOI
Jelovac A, O"Connor S, McCarron S, McLoughlin DM., Autobiographical Memory Specificity in Major Depression Treated With Electroconvulsive Therapy., The journal of ECT, 32, (1), 2016, p38-43 , Journal Article, PUBLISHED  DOI

Page 1 of 14
Semkovska M, McLoughlin DM , Retrograde autobiographical amnesia following ECT: on the difficulty of finding the baby and clearing murky bathwater, J ECT, 30, (3), 2014, p187 - 188, Journal Article, PUBLISHED
Dunne RA, McLoughlin DM, Physical treatments, Medicine , 40, 2012, p672 - 673, Notes: [ ], Journal Article, PUBLISHED
McLoughlin, DM, Vagus rules still apply., Psychological Medicine, 38, (5), 2008, p625 - 627, Journal Article, PUBLISHED
McLoughlin, DM, Review: repetitive transcranial magnetic stimulation is of unknown effectiveness in people with depression., Evidence-Based Mental Health, 6, (4), 2003, p118 - 118, Journal Article, PUBLISHED
Lovestone S, McLoughlin D., Alzheimer's disease: molecular biology and the quest for a treatment. , Care of the Elderly, 6, 1994, p149-152 , Journal Article, PUBLISHED
Cigeroglu YB, McLoughlin D., Psychotherapy training in Turkey, 1994, - 650-651, Miscellaneous, PUBLISHED


I have been investigating the neuronal signalling function of the Alzheimer's disease amyloid precursor protein (APP) and was among the first to identify the FE65 and X11 adaptor proteins as APPbinding partners. To study their functions in vivo, we have made X11 transgenic mice and have demonstrated that the X11s regulate APP processing and reduce cerebral Ab production and deposition. The neuronal X11 proteins are therefore novel therapeutic targets for Alzheimer's disease. I am now leading a research group studying behavioural and electrophysiological effects of X11- mediated reduction in cerebral Ab in an Alzheimer's animal model. On the clinical side, I have also been leading randomised controlled trials of therapeutic neuromodulation techniques (e.g. transcranial magnetic stimulation, electroconvulsive therapy) for neuropsychiatric disorders such as depression and schizophrenia. In St Patrick's Hospital and TCD, we are about to start a 5-year research programme called the EFFECT-Dep Study (enhancing the effectiveness of electroconvulsive therapy in severe depression and understanding its molecular mechanism of action). This programme is supported by a HRB Translational Research Award and its purpose is to improve ECT practice and use it to interrogate the molecular neurobiology of depression. We will carry out a definitive randomised controlled trial comparing bilateral and high-dose unilateral ECT, recruiting 140 patients with severe depression. We will also use an animal model of ECT treatment to characterise changes in global protein expression (i.e. the proteome) in both brain and blood plasma and also carry out similar studies using plasma from depressed patients recruited into the clinical trial. The results of these studies will improve clinical ECT and also help us understand better the molecular mechanism of action of ECT, as well as antidepressant drugs, and lead to identification of candidate peripheral biomarkers for depression, treatment response and depression relapse.